Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature

Episode Summary

Executive Summary: Vishwa Kaluru traces how personal loss, scientific training, and a contrarian view of drug discovery led him to found Enveda, a natural-products biotech using AI and metabolomics to turn plant chemistry into first-in-class oral medicines. The company has advanced multiple clinical programs, arguing that chemistry-first discovery can be faster, more efficient, and harder to copy than conventional target-based R&D.

Main Topics: Personal origin story and mission (Priority: 5/5): Kaluru’s mother’s leukemia and his family’s resilience shaped his lifelong goal to create medicines that help patients, especially mothers, live longer and better lives. From immunology to contrarian thinking (Priority: 5/5): Graduate work in immunotherapy taught him that major breakthroughs often come from old ideas that were once dismissed, motivating him to pursue unfinished scientific problems. Recursion and the limits of reductionist drug discovery (Priority: 4/5): At Recursion, he learned platform thinking, phenotypic discovery, and the central industry problem: drugs work in the lab but fail in people. Founding Enveda on natural products and chemistry-first discovery (Priority: 5/5): He bootstrapped Enveda to systematically interrogate plant-derived chemistry, treating natural products as a rich, underexplored source of medicines rather than 'alternative' medicine. AI, metabolomics, and the 'sequencer for chemistry' (Priority: 5/5): Enveda uses mass spectrometry, machine learning, and transformer models to infer structures and functions from complex mixtures, enabling faster discovery from plant samples. Pipeline, clinical progress, and efficiency claims (Priority: 4/5): The company has multiple programs in the clinic, including inflammatory disease, obesity, and IBD, and claims unusually fast development timelines and high success rates. Commercial strategy, defensibility, and long-term ambition (Priority: 4/5): Kaluru argues that complex natural chemistry can be both clinically powerful and hard to copy, positioning Enveda as a future 21st-century pharma company.

Key Arguments: Old, unfinished ideas can be more productive than fashionable ones because the bottlenecks are already better defined. Drug discovery should be judged by whether it changes outcomes in people, not by how elegant the biology looks in vitro. Natural products are not a relic; they are a statistically productive and underexplored source of novel biology and chemistry. AI becomes valuable when paired with the right data, especially high-quality mass spectrometry and metabolomics datasets. Phenotypic and chemistry-first discovery can outperform purely reductionist target-based approaches for complex disease. Complex natural chemistry may be harder for competitors to copy, creating a defensible moat around first-in-class assets. A platform company must eventually become a drug company and own its medicines to prove real value. Enveda’s approach appears to reduce the number of compounds needed and the time required to reach development candidates compared with industry norms.

Data Points: Founding year: 2019 - Enveda was founded in Boulder, Colorado in 2019. Bootstrap capital: $50,000 - Kaluru initially started the company with his own savings. Total capital raised: $517 million - Reported total funding raised by Enveda. Reported valuation: ~$1 billion - The company is described as having reached a unicorn valuation. Clinical candidates: 3 - Three drug candidates were already in clinical trials at the time of the interview. Phase 1b response rate: 9/9 patients - Kaluru said the lead inflammatory program saw responses in all nine patients in phase 1b. Clinical remission: >85% - He reported more than 85% disease remission within four weeks in the inflammatory program. Plant coverage by traditional analytical chemistry: ~5% of molecules detected - He said conventional methods are blind to about 19 out of 20 molecules in a plant. Development candidate timeline: 12-14 months - Average time from interesting lead to development candidate at Enveda. Compounds per development candidate: 80-120 compounds - Average number of compounds synthesized/tested to reach a development candidate. Preclinical pass rate: 14 of 15 programs - He said 14 of 15 programs passed early toxicity studies before DC nomination. Capital efficiency: 50-60% spent - He said the company had spent only about half to 60% of the capital raised while advancing multiple programs. Company size at Recursion: ~15 full-time employees - Kaluru joined Recursion when it was still very small and pre-Series A. Recursion office size: ~200 square feet - He described the early office as a small 'fishbowl' room. Time at Recursion: ~3 years - He worked there from fall 2016 to early/mid 2019. First outside angel check: $100,000 - Martin Brenner, former CSO at Recursion, made the first outside investment. Early total funding: ~$250,000 - Kaluru said he had about a quarter million dollars in the first couple of months. Personal savings used to start Enveda: $55,000 - He moved to Florida and put his savings into a Delaware C-Corp in April 2019. Obesity program status: Phase 1 - The obesity asset was described as being in phase 1 studies. Inflammatory program status: Phase 2 - The lead atopic dermatitis/asthma program had completed phase 1b and entered phase 2.

Pivotal Quotes: "“We want Enveda to be a 21st century pharma company that's around and loved for generations to come.”" — Vishwa Kaluru: He described the company’s long-term ambition and staged growth strategy. "“The easiest phenotypes of how these cells looked were monogenic diseases.”" — Vishwa Kaluru: He explained why phenotypic screening at Recursion was attractive as a discovery strategy. "“We had drugs before we had biology labs and before we had molecular biology as a formal field of investigation.”" — Vishwa Kaluru: He justified returning to chemistry-first, natural-product-based discovery.

Implications: The interview suggests AI-enabled natural-product discovery could revive a historically productive but underused source of medicines. If Enveda’s clinical results hold, it may validate chemistry-first R&D as faster, cheaper, and more defensible than conventional target-based drug discovery.